Identifying factors to predict benefit from bevacizumab in progressive glioblastoma multiforme (GBM).

被引：0
|
作者：
Gleeson, Jack Patrick
Alhusaini, Abdullah
O'Halloran, Philip
Harrold, Emily
Keegan, Niamh M.
Karadawi, Nabeeha Eltag
Mammadov, Emin
Kamel, Dalia
Egan, Keith
Molloy, Susan
Hennessy, Bryan T.
Breathnach, Oscar S.
Grogan, William
Morris, Patrick G.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e13515
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13515
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Fotemustine in recurrent or progressive glioblastoma multiforme (GBM)
    Savio, G.
    Pepe, A.
    Laudani, A.
    Leonardi, V
    Usset, A.
    Rondello, G.
    Arcuri, C.
    Palmisano, V
    Alu', M.
    Macaluso, M.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2007, 18 : 80 - 80
  • [2] Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM)
    Maron, R.
    Vredenburgh, J. J.
    Desjardins, A.
    Reardon, D. A.
    Quinn, J. A.
    Rich, J. N.
    Gururangan, S.
    Wagner, S. A.
    Salacz, M. E.
    Friedman, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Bevacizumab and irinotecan in patients with recurrent glioblastoma multiforme (GBM)
    Raval, Sumul N.
    Rule, Amy
    Hwang, Shirley S.
    NEURO-ONCOLOGY, 2006, 8 (04) : 482 - 482
  • [4] COMPUTATIONAL APPROACH TO IDENTIFYING NEUROINFLAMMATION IN GLIOBLASTOMA MULTIFORME (GBM)
    Sherman, Wendy
    Martin, Katie
    Rossell, Larissa
    Nguyen, Kelly
    Grady, Pamela
    Zimmermann, Cynthia
    Chesla, David
    Mackeigan, Jeffrey
    NEURO-ONCOLOGY, 2020, 22 : 74 - 74
  • [5] Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM)
    Raval, S.
    Hwang, S.
    Dorsett, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] BEVACIZUMAB FOR PROGRESSIVE GLIOBLASTOMA MULTIFORME: A CASE OF TREADING THE TIGHTROPE
    Majewska, Paulina
    Madhavan, Krishnaswamy
    Sioftanos, George
    NEURO-ONCOLOGY, 2018, 20 : 21 - 21
  • [7] Phase II trial of bevacizumab and erlotinib in recurrent glioblastoma multiforme (GBM)
    Sathornsumetee, Sith
    Vredenburgh, James
    Rich, Jeremy
    Desjardins, Annick
    Quinn, Jennifer
    Bota, Daniela
    Goli, Krishna
    Mathe, Alyssa
    Gururangan, Sridharan
    Friedman, Allan
    Friedman, Henry
    Reardon, David
    NEURO-ONCOLOGY, 2007, 9 (04) : 516 - 516
  • [8] Bevacizumab (B) plus irinotecan (I) in progressive temozolomide (T) resistant Glioblastoma Multiforme (GBM) - A single center experience
    Dresemann, G.
    ONKOLOGIE, 2008, 31 : 76 - 76
  • [9] Systemic Inflammatory Markers for Prediction of Bevacizumab Benefit in Glioblastoma Multiforme
    Besiroglu, Mehmet
    Shbair, Abdallah T. M.
    Yasin, Ayse Irem
    Topcu, Atakan
    Turk, Haci Mehmet
    Demir, Tarik
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2021, 31 (01): : 39 - 44
  • [10] Radiographic evaluation of recurrent glioblastoma multiforme (gbm) in patients treated with bevacizumab and irinotecan
    Andre, Jalal
    Spearman, Kenneth
    Lu, Stanley
    Raval, Sumul
    NEURO-ONCOLOGY, 2007, 9 (04) : 575 - 575
12345